If it gets authorization, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19. “This is going to change the dialogue around how to manage COVID-19,” Merck Chief Executive Robert Davis told Reuters. “An oral antiviral that can impact hospitalization risk to such a degree would be game changing,” Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security, said. A simple oral pill would be the opposite of that,” Adalja added. Molnupiravir is also being studied in a Phase 3 trial for preventing coronavirus infection in people exposed to the virus.

Source: Philippine Daily Inquirer October 01, 2021 14:48 UTC